GSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027

GSK Plc GSK has made an investment of over €250 million ($272 million) in a vaccine facility located in Belgium. 

The company plans to construct a new section dedicated to freeze-drying vaccines at the Wavre facility, the global vaccine production site, reported Bloomberg.

This move aligns with Belgium's efforts to strengthen its role as a prominent global center for health and biotechnology, mentioned the report.

Scheduled for operation in 2027, the new facility near Brussels will produce both non-living vaccines like Zona and RSV shots and live vaccines for measles and varicella. GSK aims to manufacture tens of millions of doses annually at this location.

Belgium, known for its Covid vaccine exports, invests around €1.5 billion yearly in biotech. GSK's Belgian head, Emmanuel Amory, revealed this, while GSK contributes €300-500 million annually.

Freeze-drying vaccines aim to boost stability and shelf life. GSK's innovative center aims to enhance supply reliability and vaccine quality.

Price Action: GSK shares are trading higher by 0.73% at $35.77 premarket on Wednesday.

Now Read: Illumina Announces Job Layoffs After CEO Resignation, Icahn's Board Chess Game: What's Next?